Exogenous tRNA Strategy for Non-Optimal Codon Haploinsufficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Haploinsufficiency disorders, such as Dravet Syndrome, result from insufficient expression of gene products due to non-optimal codons leading to destabilized mRNA transcripts, which reduces protein production.
Innovation Solution
Introduce exogenous tRNAs or expression vectors encoding tRNAs that hybridize to non-optimal codons to increase the abundance of these tRNAs, facilitating protein expression and stabilizing mRNA transcripts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If non-optimal codons are present in the gene, then mRNA transcript stability decreases, but protein expression can be increased by introducing exogenous tRNAs
Solution Approach 1:
The patent introduces exogenous tRNAs as intermediary molecules that mediate between the non-optimal codons in the mRNA and the protein synthesis machinery. These tRNAs specifically recognize and bind to non-optimal codons, facilitating efficient translation without destabilizing the mRNA transcript, thereby resolving the contradiction between maintaining mRNA stability and achieving high protein expression.
Solution Approach 2:
The patent changes the parameter of tRNA abundance by introducing exogenous tRNAs into the cellular system. This parameter change specifically increases the concentration of tRNAs that decode non-optimal codons, thereby improving translation efficiency and protein expression levels without altering the mRNA sequence or structure, thus maintaining mRNA stability while enhancing productivity.
2Quantity of substance
If one gene allele is inactivated, then gene product expression becomes insufficient, but introducing exogenous tRNAs can compensate for this deficiency
Solution Approach 1:
The patent converts the harmful effect of haploinsufficiency (insufficient gene product from one active allele) into a benefit by introducing exogenous tRNAs that specifically enhance the translation efficiency of the remaining active allele. This approach transforms the limiting factor (single active allele) into an opportunity for targeted intervention, where exogenous tRNAs compensate for the reduced genetic dosage and restore functional sufficiency.
3Productivity
If tRNA abundance for non-optimal codons is low, then protein production is reduced, but increasing tRNA abundance enhances protein expression
Solution Approach 1:
The patent applies preliminary action by pre-introducing exogenous tRNAs into the cellular system before protein synthesis occurs. These tRNAs are prepared in advance and accumulated to sufficient abundances, ensuring that when translation of mRNA containing non-optimal codons occurs, the necessary tRNAs are already present in adequate quantities to facilitate efficient protein production, thereby preventing translation bottlenecks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances protein expression by up to several hundred percent and stabilizes mRNA, effectively treating haploinsufficiency disorders like Dravet Syndrome.
Implementation Method 1
introducing into the cell an effective amount of a first exogenous tRNA that (i) comprises an anticodon that hybridizes to the first non-optimal codon
Data Source
AI summary
A tRNA that hybridizes to a non-optimal codon can be used to increase expression in a mammalian cell of a gene product encoded by a gene containing the non-optimal codon or to treat a haploinsufficiency disorder in a subject having a haploinsufficient gene containing the non-optimal codon.